We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Laura Mauri

Laura Mauri MD, MSc

Chief Scientific Adviser of Harvard Clinical Research Institute, Professor of Medicine, Harvard Medical School (HMS), Boston, MA
Professor of Medicine at Harvard Medical School and Physician at Brigham and Women’s Hospital where she is a practicing interventional cardiologist.  Research interests include new medical device effectiveness and late adverse events, understanding of the interactions between medical devices, general clinical practice, and concurrent pharmaceutical therapy, observational vs randomized trial methods to compare treatment strategies, and identifying methods to improve trial design and execution in order to facilitate innovation across clinical specialties.  PI of the DAPT Study, a large international randomized trial of patients undergoing percutaneous coronary intervention, to investigate the impact of antiplatelet therapy conducted in collaboration with the US Food and Drug Administration and 8 pharmaceutical and device manufacturers. Chief Scientific Adviser of Harvard Clinical Research Institute, an academic research organization with ~200 employees specialized in the full execution and leadership of clinical trials.